Please upgrade your browser.
The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10
Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR
Presentations Highlight Preclinical Data for Novel SGN-CD33A and SGN-LIV1A Programs and Breakthroughs in Research to Develop Highly Stable Linkers and More Potent Chemotypes.
We attended the Rally for Research, April 8, 2013, on the grounds of the Carnegie Library, across from the Convention Center, where the 2013 AACR Annual Meeting is taking place. This brief video examines how the event was attended. Its purpose was to make research a national priority. The rally was webcast live. Learn more about this event: http://www.rallyformedicalresearch.org/Pages/default.aspx
Maurer and three other local students will head to the Intel International Science and Engineering Fair in Phoenix May 12-17 after taking top honors among more than 1,000 students...
The study found that partial and complete kidney removal (total nephrectomy) and energy-based techniques to destroy tumors are all on the rise. Surprisingly, the patients most in need of kidney-sparing surgery are still more likely to undergo total nephrectomy.
Learn about the 2013 Annual Meeting of the American Association for Cancer Research (AACR) in this short video.
Join the more than 18,000 cancer researchers and advocates in Washington, D.C. for the biggest rally of its kind!
Dr. Stephen Keefe to present clinical data demonstrating CRLX101's combinability with Avastin® to treat renal cell carcinoma.
(NaturalNews) I'm absolutely shocked at how many people don't investigate what's really in the products they swallow. When something is sold as an herb, vitamin, superfood or supplement, they think it's automatically safe. And while the natural products industry has a truly remarkable safety record -- especially in contrast to the massive number of deaths caused by pharmaceuticals -- it still suffers from a lot of hidden toxins that are routinely used throughout the industry.
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2013, to be held April 6-10 at the Walter E. Washington Convention Center in Washington, D.C.
|NeonCRM by Neon One|